

transfer its holdings to a successor organization or is itself designated the permanent custodian of the intellectual property.

Below is the name and contact information of an individual from whom additional information concerning the organization can be obtained: Carey R. Ramos, Esq.; Paul, Weiss, Rifkind, Wharton & Garrison LLP; 1285 Avenue of the Americas; New York, NY 10019-6064.

Patricia A. Brink, Deputy Director of Operations, Antitrust Division.

[FR Doc. 2010-26734 Filed 10-25-10; 8:45 am] BILLING CODE 4410-11-M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances; Notice of Application

This is notice that on July 22, 2010, Cody Laboratories Inc., 601 Yellowstone Avenue, Cody, Wyoming 82414-9321, made application by renewal to the Drug Enforcement Administration (DEA) for registration as an importer of the basic classes of controlled substances listed in schedule II:

Table with 2 columns: Drug, Schedule. Rows include Raw Opium (9600) and Concentrate of Poppy Straw (9670).

The company plans to import narcotic raw materials for manufacturing and further distribution to its customers. The company is registered with DEA as a manufacturer of several controlled substances that are manufactured from raw opium, poppy straw, and concentrate of poppy straw.

As explained in the Correction to Notice of Application pertaining to Rhodes Technologies, 72 FR 3417 (2007), comments and requests for hearings on applications to import narcotic raw material are not appropriate.

As noted in a previous notice published in the Federal Register on September 23, 1975, (40 FR 43745), all applicants for registration to import a basic class of any controlled substances in schedule I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.

Dated: October 19, 2010.

Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2010-27023 Filed 10-25-10; 8:45 am] BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances; Notice of Application

Pursuant to Title 21 Code of Federal Regulations 1301.34(a), this is notice that on July 12, 2010, Noramco, Inc., Division of Ortho-McNeil, Inc., 500 Swedes Landing Road, Wilmington, Delaware 19801, made application by renewal to the Drug Enforcement Administration (DEA) for registration as an importer of the basic classes of controlled substances listed in schedule II:

Table with 2 columns: Drug, Schedule. Rows include Raw Opium (9600), Concentrate of Poppy Straw (9670), and Tapentadol (9780).

The company plans to import the Raw Opium (9600) and Concentrate of Poppy Straw (9670) to manufacture other controlled substances. The company plans to import Tapentadol (9780) in intermediate form for the bulk manufacture of Tapentadol (9780) which it will distribute to its customers.

No comments, objections, or requests for any hearings will be accepted on any application for registration or re-registration to import crude opium, poppy straw, concentrate of poppy straw, and coca leaves. As explained in the Correction to Notice of Application pertaining to Rhodes Technologies, 72 FR 3417 (2007), comments and requests for hearings on applications to import narcotic raw material are not appropriate.

Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances listed in schedule I or II, which fall under the authority of section 1002(a)(2)(B) of the Act [21 U.S.C. 952(a)(2)(B)] may, in the circumstances set forth in 21 U.S.C. 958(i), file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47.

Any such comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than November 26, 2010.

This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, (40 FR 43745-46), all applicants for registration to import a basic class of any controlled substances in schedule I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.

Dated: October 19, 2010.

Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2010-27025 Filed 10-25-10; 8:45 am] BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on July 12 2010, Aldrich Chemical Company Inc., DBA Isotec, 3858 Benner Road, Miamisburg, Ohio 45342-4304, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II:

Table with 2 columns: Drug, Schedule. Rows include Gamma Hydroxybutyric Acid (2010), Methaqualone (2565), Ibogaine (7260), Tetrahydrocannabinols (7370), 2,5-Dimethoxyamphetamine (7396), Psilocyn (7438), Normorphine (9313), Acetylmethadol (9601), Alphacetylmethadol except levo-alpha-cetylmethadol (9603), Normethadone (9635), Norpipanone (9636), 3-Methylfentanyl (9813).

| Drug  | Schedule |
|---|----------|
| Amphetamine (1100) .....                                  | II       |
| Methamphetamine (1105) .....                              | II       |
| Methylphenidate (1724) .....                              | II       |
| Amobarbital (2125) .....                                  | II       |
| Pentobarbital (2270) .....                                | II       |
| Secobarbital (2315) .....                                 | II       |
| 1-Phenylcyclohexylamine (7460) .....                      | II       |
| Phencyclidine (7471) .....                                | II       |
| Phenylacetone (8501) .....                                | II       |
| 1-Piperidinocyclohexanecarbonitrile (8603) .....          | II       |
| Cocaine (9041) .....                                      | II       |
| Codeine (9050) .....                                      | II       |
| Oxycodone (9143) .....                                    | II       |
| Hydromorphone (9150) .....                                | II       |
| Benzoylcegonine (9180) .....                              | II       |
| Ethylmorphine (9190) .....                                | II       |
| Hydrocodone (9193) .....                                  | II       |
| Isomethadone (9226) .....                                 | II       |
| Meperidine (9230) .....                                   | II       |
| Meperidine intermediate-A (9232) .....                    | II       |
| Meperidine intermediate-B (9233) .....                    | II       |
| Methadone (9250) .....                                    | II       |
| Methadone intermediate (9254) .....                       | II       |
| Dextropropoxyphene, bulk, (non-dosage forms) (9273) ..... | II       |
| Morphine (9300) .....                                     | II       |
| Thebaine (9333) .....                                     | II       |
| Levo-alphaacetylmethadol (9648) .....                     | II       |
| Oxymorphone (9652) .....                                  | II       |

The company plans to manufacture small quantities of the listed controlled substances to produce isotope labeled standards for drug testing and analysis.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than December 27, 2010.

Dated: October 19, 2010.

**Joseph T. Rannazzisi,**  
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2010-27018 Filed 10-25-10; 8:45 am]  
BILLING CODE 4410-09-P

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlled Substances; Notice of Application**

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on September 8, 2009 Cedarburg Pharmaceuticals, Inc., 870

Badger Circle, Grafton, Wisconsin 53024, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II:

| Drug                               | Schedule |
|------------------------------------|----------|
| Tetrahydrocannabinols (7370) ..... | I        |
| Dihydromorphine (9145) .....       | I        |
| Dihydrocodeine (9120) .....        | II       |
| Oxycodone (9143) .....             | II       |
| Hydromorphone (9150) .....         | II       |
| Hydrocodone (9193) .....           | II       |
| Remifentanil (9739) .....          | II       |
| Sufentanil (9740) .....            | II       |
| Fentanyl (9801) .....              | II       |

The company plans to manufacture the listed controlled substances in bulk for distribution to its customers.

In reference to drug code 7370 the company plans to bulk manufacture a synthetic Tetrahydrocannabinol. No other activity for this drug is authorized for this registration.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than December 27, 2010.

Dated: October 19, 2010.

**Joseph T. Rannazzisi,**  
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2010-27021 Filed 10-25-10; 8:45 am]  
BILLING CODE 4410-09-P

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlled Substances; Notice of Application**

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on September 3, 2010, Johnson Matthey Inc., Custom Pharmaceuticals Department, 2003 Nolte Drive, West Deptford, New Jersey 08066-1742, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II:

| Drug                                   | Schedule |
|--|----------|
| Gamma Hydroxybutyric Acid (2010) ..... | I        |
| Tetrahydrocannabinols (7370) .....     | I        |
| Dihydromorphine (9145) .....           | I        |
| Difenoxin (9168) .....                 | I        |
| Propiram (9649) .....                  | I        |
| Amphetamine (1100) .....               | II       |
| Methamphetamine (1105) .....           | II       |
| Lisdexamfetamine (1205) .....          | II       |
| Methylphenidate (1724) .....           | II       |
| Nabilone (7379) .....                  | II       |
| Cocaine (9041) .....                   | II       |
| Codeine (9050) .....                   | II       |
| Dihydrocodeine (9120) .....            | II       |
| Oxycodone (9143) .....                 | II       |
| Hydromorphone (9150) .....             | II       |
| Ecgonine (9180) .....                  | II       |
| Hydrocodone (9193) .....               | II       |
| Meperidine (9230) .....                | II       |
| Methadone (9250) .....                 | II       |
| Methadone intermediate (9254) .....    | II       |
| Morphine (9300) .....                  | II       |
| Thebaine (9333) .....                  | II       |
| Oxymorphone (9652) .....               | II       |
| Noroxymorphone (9668) .....            | II       |
| Alfentanil (9737) .....                | II       |
| Remifentanil (9739) .....              | II       |
| Sufentanil (9740) .....                | II       |
| Fentanyl (9801) .....                  | II       |

The company plans to manufacture the listed controlled substances in bulk for sale to its customers.

Any other such applicant, and any person who is presently registered with DEA to manufacture such a controlled substance, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than December 27, 2010.

Dated: October 19, 2010.

**Joseph T. Rannazzisi,**  
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2010-27019 Filed 10-25-10; 8:45 am]  
BILLING CODE 4410-09-P

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlled Substances; Notice of Application**

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on July 16, 2010, Chemic Laboratories, Inc., 480 Neponset Street, Building 7, Canton, Massachusetts 02021, made application